Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18705322 | 0.88 | SMN1; SMN2 (0.51) | NPC1RAB9ASMN1; SMN2MAPTEGFR | |
| SCHEMBL1668317 | 0.87 | EPHX2 (0.59) | NPC1RAB9ASMN1; SMN2MAPTPOLB | |
| SCHEMBL18705329 | 0.86 | ALDH1A1 (0.46) | RAB9ASMN1; SMN2LMNAALDH1A1DGAT1 | |
| SCHEMBL750357 | 0.85 | EPHX2 (0.58) | NPC1RAB9ASMN1; SMN2MAPTPOLB | |
| SCHEMBL8835699 | 0.84 | GLA (0.55) | GAANPSR1CA12CA1CA2 | |
| SCHEMBL750350 | 0.83 | NPC1 (0.60) | NPC1RAB9ASMN1; SMN2MAPTPOLB | |
| SCHEMBL13459410 | 0.83 | NPC1 (0.76) | NPC1RAB9ASMN1; SMN2MAPTPOLB | |
| SCHEMBL751287 | 0.81 | NPC1 (0.49) | NPC1RAB9ASMN1; SMN2MAPTPOLB | |
| SCHEMBL4856473 | 0.80 | EPHX2 (0.54) | NPC1RAB9ASMN1; SMN2MAPTPOLB | |
| SCHEMBL2399503 | 0.80 | CA12 (0.58) | NPC1RAB9ASMN1; SMN2MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138209-B2 | Substituted picolinamides as MAO-B inhibitors useful for treating obesity | JENRIN DISCOVERY, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-8138209-B2 | Substituted picolinamides as MAO-B inhibitors useful for treating obesity | JENRIN DISCOVERY, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| WO-2007008963-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2007-01-18 | — | — | WO | disclosed |
| US-20070015734-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2007-01-18 | — | — | US | disclosed |
| US-20070015734-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015734-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | MAOB, MAOA, GPR119 | NPC1 1101/4885RAB9A 2997/4885SMN1; SMN2 3865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.